Search for: "Purdue Pharmaceutical Products L.P."
Results 1 - 20
of 35
Sorted by Relevance
|
Sort by Date
7 Jun 2010, 9:59 pm
Noonan -- In Purdue Pharma Products L.P. v. [read post]
25 Aug 2013, 9:21 pm
Purdue Pharmaceutical Products L.P. et al. v. [read post]
10 Nov 2013, 9:03 pm
Laboratories, Inc.; Purdue Pharmaceuticals... [read post]
1 Feb 2016, 10:43 am
Plaintiffs-appellantsPurdue Pharma L.P., The P.F. [read post]
25 Jan 2007, 10:00 pm
Purdue Pharmaceuticals L.P., 218 F.R.D. 590 (S.D. [read post]
7 Dec 2011, 11:32 am
Purdue Pharma, L.P., 343 F. [read post]
14 Jun 2010, 6:12 pm
Purdue Pharma Products v. [read post]
18 Aug 2010, 12:19 am
and industrial applicability on 7 October: Eli Lilly & Co v Human Genome Sciences Inc (IPKat) Nuvigil (Armodafinil) – US: Cephalon and Mylan Pharmaceuticals agree to drop two patents from Nuvigil patent suit (Patent Docs) OxyContin (Oxycodone) – Patent infringement complaint filed following a Paragraph IV certification: Purdue Pharma L.P. et al. v. [read post]
24 Jul 2012, 7:58 pm
Keating as a basis for the STOPP Act is the tamper-resistant version of Purdue Pharma L.P. [read post]
24 Jun 2010, 5:00 am
Playtex Family Products Corp., 168 F.R.D. 292 (D. [read post]
18 Sep 2016, 6:03 pm
, No. 16-296 (OxyContin patent – when is an element ‘inherently’ disclosed by the prior art for anticipation purposes) Obviousness: Purdue Pharma L.P. v. [read post]
24 Feb 2011, 1:49 pm
Teva Pharmaceuticals, 726 F. [read post]
13 May 2010, 4:58 pm
Kappos (Orange Book Blog) (FDA Law Blog) OxyContin (Oxycodone) – US: Patent infringement suit following a Paragraph IV certification: Purdue Pharma L.P. et al v. [read post]
17 Feb 2010, 5:10 am
(IP Tango) Poland: differences in pharmaceutical trade marks (Class 46) South Africa: Court of the Commissioner of Patents: Interdict pends ‘pending’ decision: Sanofi v Cipla Medpro (Afro-IP) UK: Official UK patent law reports focus on SPCs (The SPC Blog) US: Pruning priority to prolong the patent – US patent covering ‘methods and compositions for stimulating the immune system’ (12:01 Tuesday) US: Bio sends letter on SACGHS Report to HHS Secretary Sebelius… [read post]
13 Sep 2023, 1:57 am
Purdue Pharma L.P., et al. [read post]
16 Jan 2017, 5:44 pm
, No. 16-296 (OxyContin patent – when is an element ‘inherently’ disclosed by the prior art for anticipation purposes) Obviousness: Purdue Pharma L.P. v. [read post]
14 Nov 2016, 9:16 am
, No. 16-296 (OxyContin patent – when is an element ‘inherently’ disclosed by the prior art for anticipation purposes) Obviousness: Purdue Pharma L.P. v. [read post]
8 Feb 2017, 3:09 am
, No. 16-296 (OxyContin patent – when is an element ‘inherently’ disclosed by the prior art for anticipation purposes) Obviousness: Purdue Pharma L.P. v. [read post]
5 May 2009, 5:00 am
Purdue Pharma, L.P., 292 F. [read post]
28 Sep 2016, 8:39 am
, No. 16-296 (OxyContin patent – when is an element ‘inherently’ disclosed by the prior art for anticipation purposes) Obviousness: Purdue Pharma L.P. v. [read post]
